Perspective Therapeutics, Inc. (CATX)

Market Cap	143.66M
Revenue (ttm)	1.45M
Net Income (ttm)	-79.28M
Shares Out	74.05M
EPS (ttm)	-1.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	807,102
Open	1.860
Previous Close	1.850
Day's Range	1.760 - 1.935
52-Week Range	1.600 - 19.100
Beta	1.21
Analysts	Strong Buy
Price Target	13.89 (+625.33%)
Earnings Date	May 12, 2025

About CATX

Perspective Therapeutics, Inc., together with its subsidiaries, engages in the development and commercialization of precision-targeted alpha therapies (TAT) in the United States It discovers, and develop its initial drug candidate VMT-α-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumours that have not previously received peptide targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a c...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1983
• Employees: 140
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CATX

Financial Performance

In 2024, Perspective Therapeutics's revenue was $1.45 million, an increase of 1.39% compared to the previous year's $1.43 million. Losses were -$79.28 million, 70.5% more than in 2023.

Analyst Forecast

According to 10 analysts, the average rating for CATX stock is "Strong Buy." The 12-month stock price forecast is $13.89, which is an increase of 625.33% from the latest price.

Price Target

$13.89

(625.33% upside)

Analyst Consensus: Strong Buy